Intravitreal injection of ketorolac tromethamine in patients with diabetic macular edema refractory to retinal photocoagulation;Injeção intravítrea de cetorolaco de trometamina em pacientes com edema macular diabético refratário à fotocoagulacão retiniana

Arquivos Brasileiros de Oftalmologia

Volumn 73, Issue 4, 2010, Pages 338-342

  do Ceu Afonso Reis, Andreia ^a   Vianna, Raul Nunes Galvarro ^a   Dos Reis, Ricardo Siqueira Mendes ^a   Cardoso, Gilberto Perez ^a  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Diabetic retinopathy drug therapy; Injections; Intraocular pressure; Ketorolac tromethanine administration dosage; Laser coagulation; Macular edema drug therapy; Retina drug effects; Visual acuity; Vitreous body

Indexed keywords

KETOROLAC TROMETAMOL;

ANALYSIS OF VARIANCE; ARTICLE; CASE CONTROL STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; LASER COAGULATION; OPTICAL COHERENCE TOMOGRAPHY; PROSPECTIVE STUDY; RETINA MACULA EDEMA; TIME; TREATMENT OUTCOME; VISUAL ACUITY;

ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; DIABETES COMPLICATIONS; DIABETIC RETINOPATHY; HUMANS; INTRAVITREAL INJECTIONS; KETOROLAC TROMETHAMINE; LIGHT COAGULATION; MACULAR EDEMA; PROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 78449238708     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492010000400007     Document Type: Article

References (12)

1. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Ophthalmology. 1987;94(7):761-74.
2. Weinreb RN, Kashiwagi K, Kashiwagi F. Prostaglandins increased matrix metallopro-teinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997;38(13):2772-80.
3. Dare A, Castro L, Lavinsky D, Navajas E, Cardillo JÁ. Novos horizontes no tratamento do edema de macula diabético: fotocoagulaçâo macular seletiva com micropulso de diodo 810nm. Retina e Vítreo. 2007;13:16-20.
4. Joussen AM, Smyth N, Niessen C. Pathophysiology of diabetic macular edema. Dev Ophthalmol. 2007;39:1-12.
5. Furlani BA, Meyer CH, Rodrigues EB, Maia M, Farah ME, Holz FG. Emerging pharmacotherapies for diabetic macular edema. Expert Opin Emerg Drugs. 2007; 12(4):591-603.
6. Simó R, Hernández C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutics strategy. Diabetologia. 2008;51(9):1574-80.
7. Wafapoor H, McCluskey J. Intravitreal ketorolac as a treatment of diabetic and non-diabetic macular edema. Invest Ophthalmol Vis Sci. 2006;47:E-abstract 4227.
8. Margalit E, Kugle LJ, Brumm MV, Meza JL, Kompella UB, Escobar ER, et al. The safety of intraocular ketorolac in rabbits. Invest Ophthalmol Vis Sci. 2006;47(5): 2093-9.
9. Sánchez-Tocino H, Alvarez-Vidal A, Maldonado MJ, Moreno-Montañés J, García-Layana A. Retinal thickness study with optical coherence tomography in patients with diabetes. Invest Ophthalmol Vis Sci. 2002;43(5):1588-94.
10. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54(1):1-32.
11. Yilmaz T, Weaver CD, Gallagher MJ, Cordero-Coma M, Cervantes-Castaneda RA, Klisovic D, et al. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology. 2009; 116(5): 912-3.
12. Kim ST, Adams NA, Toma HS, Belair ML, Thorne JE, Green WR, et al. Safety of intravitreal ketorolac and diclofenac: an electroretinographic and histopathologic study. Retina. 2008;28(4):595-605.